- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07712575
A Study of V132 in Healthy Older Participants (V132-001)
A Phase 1, Randomized, Double-Blind, Comparator-Controlled Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V132 in Healthy Older Participants
The goal of this study is to learn about the safety and immune response to the V132 vaccine in healthy older adults.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Toll Free Number
- Número de teléfono: 1-888-577-8839
- Correo electrónico: Trialsites@msd.com
Ubicaciones de estudio
-
-
California
-
Anaheim, California, Estados Unidos, 92801
- Reclutamiento
- Anaheim Clinical Trials ( Site 0006)
-
Contacto:
- Study Coordinator
- Número de teléfono: 714-774-7777
-
-
Florida
-
Hallandale, Florida, Estados Unidos, 33009
- Reclutamiento
- Velocity Clinical Research, Hallandale Beach ( Site 0003)
-
Contacto:
- Study Coordinator
- Número de teléfono: 954-455-5757
-
Hollywood, Florida, Estados Unidos, 33024
- Reclutamiento
- Research Centers of America ( Hollywood ) ( Site 0009)
-
Contacto:
- Study Coordinator
- Número de teléfono: 954-990-7649
-
South Miami, Florida, Estados Unidos, 33143
- Reclutamiento
- QPS-MRA, LLC-Early Phase ( Site 0001)
-
Contacto:
- Study Coordinator
- Número de teléfono: 305-722-0970
-
-
Missouri
-
Springfield, Missouri, Estados Unidos, 65802
- Reclutamiento
- Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)
-
Contacto:
- Study Coordinator
- Número de teléfono: 417-831-2048
-
-
Nebraska
-
Lincoln, Nebraska, Estados Unidos, 68510
- Reclutamiento
- Velocity Clinical Research Lincoln ( Site 0007)
-
Contacto:
- Study Coordinator
- Número de teléfono: 531-530-2800
-
Omaha, Nebraska, Estados Unidos, 68134
- Reclutamiento
- Velocity Clinical Research, Omaha ( Site 0008)
-
Contacto:
- Study Coordinator
- Número de teléfono: 402-933-6500
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43215
- Reclutamiento
- Remington-Davis, Inc. ( Site 0005)
-
Contacto:
- Study Coordinator
- Número de teléfono: 614-487-2560
-
-
Rhode Island
-
East Greenwich, Rhode Island, Estados Unidos, 02818
- Reclutamiento
- Velocity Clinical Research, Providence ( Site 0010)
-
Contacto:
- Study Coordinator
- Número de teléfono: 401-739-9350
-
-
Texas
-
League City, Texas, Estados Unidos, 77573
- Reclutamiento
- University of Texas Medical Branch ( Site 0004)
-
Contacto:
- Study Coordinator
- Número de teléfono: 832-340-2313
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
The key inclusion criteria include but are not limited to the following:
- Is in good health
- Has body mass index (BMI) within 18.0 to 35.0 kg/m^2 (inclusive)
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
- Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination
- Has received a pneumococcal polysaccharide vaccine in the previous 10 years, has received any pneumococcal conjugate vaccine at any time prior to this study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Part 1: Dose Escalation
Participants will receive single intramuscular (IM) doses of a V132 formulation or comparator regimen at varying dose levels. |
Experimental Experimental Experimental Active Comparator Active Comparator |
|
Experimental: Part 2: Dose Expansion
Participants will receive single IM doses of a V132 formulation or comparator regimen. Doses will be determined based on review of Part 1 data and will not exceed maximum dose level assessed in Part 1. |
Experimental Experimental Experimental Active Comparator Active Comparator |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Participants with Immediate Reactions Occurring Within 30 Minutes After Any Vaccination
Periodo de tiempo: Up to approximately 30 minutes post vaccination
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with immediate reactions occurring within 30 minutes after any vaccination will be reported. |
Up to approximately 30 minutes post vaccination
|
|
Percentage of Participants with a Solicited Injection-site Adverse Event
Periodo de tiempo: Up to approximately 7 days post vaccination
|
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited injection-site AEs assessed are redness/erythema, swelling, and tenderness/pain. The percentage of participants with a solicited injection-site adverse event will be reported. |
Up to approximately 7 days post vaccination
|
|
Percentage of Participants with a Solicited Systemic Adverse Event
Periodo de tiempo: Up to approximately 7 days post vaccination
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The solicited systemic AEs assessed are muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with a solicited systemic adverse event will be reported. |
Up to approximately 7 days post vaccination
|
|
Percentage of Participants With at Least 1 Unsolicited Adverse Event
Periodo de tiempo: Up to approximately 28 days post vaccination
|
An unsolicited AE is an AE that was not solicited using a vaccination report card (VRC) and that is communicated by a participant (or their legally acceptable representative, if applicable). Unsolicited AEs include serious and nonserious AEs. The percentage of participants with at least 1 unsolicited adverse event will be reported. |
Up to approximately 28 days post vaccination
|
|
Percentage of Participants with a Serious Adverse Event
Periodo de tiempo: Up to approximately 12 months post vaccination
|
A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event. The percentage of participants that experienced 1 or more SAEs will be reported. |
Up to approximately 12 months post vaccination
|
|
Percentage of Participants With at Least 1 Medically Attended Adverse Event
Periodo de tiempo: Up to approximately 12 months post vaccination
|
A medically attended adverse event (MAAE) is an AE in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency room visit, office visit, or an urgent care visit with any medical personnel for any reason. The percentage of participants with at least 1 MAAE will be reported. |
Up to approximately 12 months post vaccination
|
|
Percentage of Participants Who Experienced an Adverse Event of Clinical Interest
Periodo de tiempo: Up to approximately 12 months post vaccination
|
Events of clinical interest (ECIs) are defined as an overdose of Sponsor's product, drug-induced liver injury events, or potential immune-mediated diseases (pIMDs). The percentage of participants who experienced an adverse event of clinical interest will be reported. |
Up to approximately 12 months post vaccination
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA)
Periodo de tiempo: Up to approximately 28 days post vaccination
|
Opsonophagocytic activity (OPA) for serotypes in V132 formulations will be determined using a multiplexed opsonophagocytic assay (MOPA). Geometric Mean Titer (GMT) of serotype-specific OPA will be reported. |
Up to approximately 28 days post vaccination
|
|
Geometric Mean Fold Rise from Baseline of Serotype-specific OPA
Periodo de tiempo: Baseline (pre-vaccination) and 28 days post vaccination
|
The Geometric Mean Fold Rise (GMFR) from baseline in serotype-specific OPA GMTs for serotypes in V132 formulations will be determined using a multiplexed opsonophagocytic assay (MOPA). GMFR is defined as the geometric mean of the ratio of concentration at Day 28 post vaccination divided by concentration at baseline. |
Baseline (pre-vaccination) and 28 days post vaccination
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Medical Director, Merck Sharp & Dohme LLC
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- V132-001
- V132-001 (Otro identificador: MSD)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .